Event Coverage Sponsored by
A panel was moderated by Greg Stock, president and CEO, Signum BioSciences Director; program director, technology and society, UCLA School of Medicine. Distinguished panelists included Lynne Greene, global president, Clinique; Howard Murad, MD, CEO and founder, Murad, Inc.; and Nicole Fourgoux, AVP, Garnier Nutritioniste.
“The first wave of change in the next decade will show tailoring the genetics of our own biochemistry and addressing problems before they occur,” said Stock. “The lines are blurring between treatment and prevention, medicine and personal care, and need and desire. The beauty industry inhabits a gray regulatory environment, particularly in the area of antiaging, and the challenges will include keeping things fresh and addressing the question of whether you are selling beauty and health or the feel of beauty and health.”
“Years ago, we had ‘hope in a jar,’ over time the hope has become better and better,” said Murad. “Your skin is connected to every part of your body and is a microcosm of the whole body. If you improve the quality of your skin, you’re improving the quality of your body.”
“From hope in a jar to the antiaging pill to which Dr. Stock alluded, we are almost at the ‘illusion’ place now, meaning, ‘I think, therefore I am,’” said Greene. “Thirty or 40 years ago, there was a certain amount of letting go. There isn’t that same feeling anymore. Women want to look good no matter how, and we are selling within the psychological headset of the consumer.”